SCHEMBL6368252

SCHEMBL6368252

COC(=O)CC(=O)CC(O)(CCc1ccccc1CO)C(C)C

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 3/20 0.41
CYP4A11 Q02928 3/20 0.41
SLC13A5 Q86YT5 2/20 0.34
KDM4E B2RXH2 2/20 0.33
TSHR P16473 3/20 0.32
MTNR1A P48039 1/20 0.32
MTNR1B P49286 1/20 0.32
POLB P06746 1/20 0.32
USP2 O75604 1/20 0.32
PRNP P04156 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32
HPGD P15428 1/20 0.30
HTT P42858 1/20 0.30
ALDH1A1 P00352 2/20 0.30
LMNA P02545 1/20 0.30
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6296312 0.89 CYP4F2 (0.53) CYP4F2CYP4A11SLC13A5TSHRPRNP
SCHEMBL6699504 0.89 CYP4F2 (0.53) CYP4F2CYP4A11SLC13A5TSHRPRNP
SCHEMBL6296311 0.89 CYP4F2 (0.53) CYP4F2CYP4A11SLC13A5TSHRPRNP
SCHEMBL6298285 0.86 KMT2A (0.40) ALDH1A1LMNA
SCHEMBL6297681 0.85 ALDH1A1 (0.32) HTTALDH1A1
SCHEMBL6296347 0.82 BACE1 (0.41) SLC13A5MTNR1AMTNR1B
SCHEMBL6296426 0.82 CYP4F2 (0.43) CYP4F2CYP4A11SLC13A5KDM4EMTNR1A
SCHEMBL6296429 0.82 CYP4F2 (0.43) CYP4F2CYP4A11SLC13A5KDM4EMTNR1A
SCHEMBL6296751 0.81 SLC13A5 (0.43) CYP4F2CYP4A11SLC13A5
SCHEMBL6296754 0.81 SLC13A5 (0.43) CYP4F2CYP4A11SLC13A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040106606-A1 HIV protease inhibitors BOYER FREDERICK EARL (US) 2004-06-03 US claimed
US-6528510-B1 Dihydropyrones with tethered heterocycles; 3-(2-tert-Butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6 -isopropyl-6-(2-pyridin-4-yl-ethyl)-5,6-dihydro-pyran - 2-one; WARNER-LAMBERT COMPANY 2003-03-04 US claimed
EP-1112269-A2 HIV PROTEASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-07-04 EP claimed
WO-2000015634-A2 HIV PROTEASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2000-03-23 WO claimed
US-20050075390-A1 HIV protease inhibitors AGOURON PHARMACEUTICALS, INC. 2005-04-07 US disclosed
US-6528510-B1 Dihydropyrones with tethered heterocycles; 3-(2-tert-Butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6 -isopropyl-6-(2-pyridin-4-yl-ethyl)-5,6-dihydro-pyran - 2-one; WARNER-LAMBERT COMPANY 2003-03-04 US disclosed
EP-1112269-A2 HIV PROTEASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-07-04 EP disclosed
WO-2000015634-A2 HIV PROTEASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2000-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106606-A1 HIV protease inhibitors DNPEP, PREP, PEPD CYP4F2 2266/4885CYP4A11 1588/4885SLC13A5 4373/4885
US-20050075390-A1 HIV protease inhibitors DNPEP, PREP, PEPD CYP4F2 2491/4885CYP4A11 1825/4885SLC13A5 4286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.